Oncocyte to Participate in Fireside Chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Rhea-AI Summary

Oncocyte Corporation (NYSE American: OCX) announced its participation in a Fireside Chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021, at 4:30 PM EST. This event will be accessible via a live webcast and will later have a replay available on the company's investor website. Oncocyte focuses on molecular diagnostics to enhance cancer care through proprietary tests such as DetermaRx and DetermaIO, aimed at improving patient outcomes and driving company revenue growth.

IRVINE, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, announced today that management is scheduled to participate in a Fireside Chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Presentation details:
Date: February 18, 2021
Time: 4:30pm EST

The presentation will be accessible via a live webcast at https://wsw.com/webcast/btig3/ocx/

Following the conference, a webcast replay of the presentation will be available on the Investor section of the company’s website, www.oncocyte.com.

About Oncocyte Corporation
Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company’s tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company. Oncocyte recently launched DetermaRx™, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy. Oncocyte has also launched DetermaIO™, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, as a research use only tool for pharmaceutical and academic clinical trials. To complement DetermaIO, the company anticipates launching DetermaTx™, a test to assess mutational status of a tumor to help identify the appropriate targeted therapy, in the second half of 2021. The Company also continues with the development of DetermaMx™ as the company seeks to expand into the blood-based monitoring market. Oncocyte’s pharmaceutical services provide pharmaceutical companies who are developing new cancer treatments a full suite of molecular testing services to support the drug development process.

DetermaRx, DetermaIO, DetermaMx, and DetermaTx are trademarks of Oncocyte Corporation. Therasure is a trademark of Chronix Biomedical Inc.

Investor Contact
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
bob@lifesciadvisors.com

FAQ

When is Oncocyte's presentation at the BTIG Conference?

Oncocyte's presentation is scheduled for February 18, 2021, at 4:30 PM EST.

How can I access Oncocyte's presentation at the conference?

The presentation can be accessed via a live webcast at https://wsw.com/webcast/btig3/ocx/. A replay will be available on the company's investor website afterward.

What is the purpose of Oncocyte Corporation's diagnostics?

Oncocyte's mission is to provide actionable answers to enhance cancer care at critical decision points through molecular diagnostics.

What is DetermaRx, and what does it do?

DetermaRx is a test launched by Oncocyte that identifies early-stage lung cancer patients at high risk of recurrence post-surgery and predicts their benefit from adjuvant chemotherapy.

What future products is Oncocyte planning to launch?

Oncocyte plans to launch DetermaTx, a test for assessing tumor mutational status, in the second half of 2021 and is developing DetermaMx for blood-based monitoring.